Benefits and risks of erythrocyte-stimulating agents

doi:10.5410/wjcu.v3.i3.258

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 3, Issue 3

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7072)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-5) series.

Item

Count

PDF

364

WORD

291

HTML

4297

Tables (1-5)

169

Sum=5121

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

954

Download

997

Sum=1951

Nov 24, 2014 (publication date) through Aug 29, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Clinical Urology

ISSN

2219-2816

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Urol. Nov 24, 2014; 3(3): 258-263
Published online Nov 24, 2014. doi: 10.5410/wjcu.v3.i3.258

Benefits and risks of erythrocyte-stimulating agents

Daisuke Katagiri, Fumihiko Hinoshita

Daisuke Katagiri, Division of Nephrology and Endocrinology, The University of Tokyo, Tokyo 162-8655, Japan

Fumihiko Hinoshita, Department of Nephrology, National Center for Global Health and Medicine, Tokyo 162-8655, Japan

Author contributions: Katagiri D and Hinoshita F contributed to this paper.

Correspondence to: Fumihiko Hinoshita, MD, PhD, Department of Nephrology, National Center for Global Health and Medicine, 1-21-1 Toyama Shinjuku-ku, Tokyo 162-8655, Japan. fhinoshi@hosp.ncgm.go.jp

Telephone: +81-3-32027181 Fax: +81-3-32071038

Received: April 24, 2014
Revised: June 5, 2014
Accepted: July 17, 2014
Published online: November 24, 2014
Processing time: 208 Days and 19.5 Hours

Core Tip

Core tip: Renal anemia is a common clinical problem in patients with severe chronic kidney disease. To overcome the shortage of endogenous erythropoietin (EPO), administration of exogenous EPO is an effective treatment. The advent of recombinant human erythropoietin (rHu-EPO) products has dramatically changed the therapeutic strategy and has shown outstanding effectiveness in patients with renal anemia. Here we discuss the treatment of renal anemia and the adverse effects of rHu-EPO.